These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20373463)

  • 21. [Non-alcoholic fatty liver disease and cardiovascular risk].
    Abel T; Fehér J
    Orv Hetil; 2008 Jul; 149(28):1299-305. PubMed ID: 18617457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment.
    Rahimi RS; Landaverde C
    Nutr Clin Pract; 2013 Feb; 28(1):40-51. PubMed ID: 23286927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [NASH (non-alcoholic steatohepatitis): fatty liver or fatal liver disease?].
    Roeb E
    Zentralbl Chir; 2014 Apr; 139(2):168-74. PubMed ID: 22441997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The challenging patient: HCV and alcoholic liver disease.
    Lucey MR; Lake JR
    Liver Transpl; 2007 Nov; 13(11 Suppl 2):S87-8. PubMed ID: 17969072
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
    Briceño J; Ciria R; Pleguezuelo M; de la Mata M; Muntané J; Naranjo A; Sánchez-Hidalgo J; Marchal T; Rufián S; López-Cillero P
    Liver Transpl; 2009 Jan; 15(1):37-48. PubMed ID: 19109846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of alcohol use disorder patients affected by liver cirrhosis and/or hepatocellular carcinoma awaiting liver transplantation.
    Testino G; Leone S; Borro P
    Minerva Med; 2016 Aug; 107(4):223-38. PubMed ID: 27148681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation.
    Sourianarayanane A; Arikapudi S; McCullough AJ; Humar A
    Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):481-487. PubMed ID: 28253211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic steatohepatitis and the metabolic syndrome.
    Jiang J; Torok N
    Metab Syndr Relat Disord; 2008 Mar; 6(1):1-7. PubMed ID: 18370830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokines in alcoholic and nonalcoholic steatohepatitis.
    Tilg H; Diehl AM
    N Engl J Med; 2000 Nov; 343(20):1467-76. PubMed ID: 11078773
    [No Abstract]   [Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease.
    Adams LA; Angulo P; Lindor KD
    CMAJ; 2005 Mar; 172(7):899-905. PubMed ID: 15795412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-alcoholic fatty liver disease.
    Tuyama AC; Chang CY
    J Diabetes; 2012 Sep; 4(3):266-80. PubMed ID: 22564417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study.
    Unger LW; Herac M; Staufer K; Salat A; Silberhumer G; Hofmann M; Trauner M; Rasoul-Rockenschaub S; Soliman T; Reiberger T; Berlakovich GA
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):309-316. PubMed ID: 27922486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of alcoholic liver disease.
    Day CP
    Liver Transpl; 2007 Nov; 13(11 Suppl 2):S69-75. PubMed ID: 17969070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome.
    El Atrache MM; Abouljoud MS; Divine G; Yoshida A; Kim DY; Kazimi MM; Moonka D; Huang MA; Brown K
    Clin Transplant; 2012; 26(5):E505-12. PubMed ID: 23061759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silent non-alcoholic fatty liver disease-a clinical-histological study.
    Sorrentino P; Tarantino G; Conca P; Perrella A; Terracciano ML; Vecchione R; Gargiulo G; Gennarelli N; Lobello R
    J Hepatol; 2004 Nov; 41(5):751-7. PubMed ID: 15519647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis.
    Contos MJ; Cales W; Sterling RK; Luketic VA; Shiffman ML; Mills AS; Fisher RA; Ham J; Sanyal AJ
    Liver Transpl; 2001 Apr; 7(4):363-73. PubMed ID: 11303298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histological assessment of non-alcoholic fatty liver disease.
    Hübscher SG
    Histopathology; 2006 Nov; 49(5):450-65. PubMed ID: 17064291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic steatohepatitis.
    Brunt EM
    Semin Liver Dis; 2004 Feb; 24(1):3-20. PubMed ID: 15085483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation.
    Watt KD
    Liver Transpl; 2012 Nov; 18 Suppl 2():S52-8. PubMed ID: 22821716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.